Table 1: Baseline demographic and laboratory data.

PBC(N=226)PBC/SS(N=56)P value

Age (years)52.5(43.0,62.0)51.5(45.0,58.8)0.778
Sex, n (%)0.123
Female189(83.6)52(92.9)
Male37(16.4)4(7.1)
PLT (× 109/L)127.0(84.0,192.8)112.0(70.5,171.8)0.244
INR1.03(0.97,1.11)1.01(0.97,1.08)0.334
Alb (g/L)41.4(35.1,44.9)40.2(36.5,43.6)0.369
Cr (μmol/L)60.0(52.8,71.0)62.1(53.5,68.0)0.635
TB (μmol/L)19.3(13.4,29.9)16.1(12.8,25.3)0.182
ALT (IU/L)56.5(34.8,82.0)62.0(40.0,88.5)0.206
AST (IU/L)75.0(48.0,110.0)65.5(44.0,97.0)0.184
ALP (IU/L)280.5(159.8,431.3)274.0(143.0,405.6)0.233
GGT (IU/L)257.5(127.8,459.0)237.0(95.8,421.5)0.340
Anti-AMA (%)162(71.7)39(69.2)0.619
ANA (%)210(92.9)56(100.0)0.041
IgG (g/L)16.3(14.2,19.4)19.3(15.5,22.2)0.001
IgM (g/L)3.6(2.3,5.9)3.7(2.3,5.0)0.788
Fib-43.6(1.9,7.1)4.2(2.4,8.6)0.134
APRI,
splenomegaly
1.3(0.7,2.2),
71(31.4%)
1.7(0.8.2.9),
19(33.9%)
0.064,
0.718
Duration of follow-up (months)21.0(14.0,38.3)28.0(11.0,65.0)0.256

Data are expressed as the median (interquartile range); PLT, platelet; INR, international normalized ratio; Alb, albumin; Cr, creatinine; TB, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; anti-AMA, antimitochondrial antibody; ANA, antinuclear antibody; Fib-4, fibrosis score; APRI, aspartate aminotransferase/platelet ratio index; IgG, immunoglobulin G; IgM, immunoglobulin M; SS, Sjögren’s syndrome; and PBC, primary biliary cholangitis.